newsfilter
← Latest News
PR Newswire·

Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

SLS-002 demonstrated early and persistent clinically meaningful reductions in symptoms of depression and acute suicidality Robust Response and Remission Rates were observed using the Montgomery-Åsberg Depression Rating